<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860366</url>
  </required_header>
  <id_info>
    <org_study_id>URICOICTUS-1-2007</org_study_id>
    <secondary_id>EudraCT 2007-002687-95</secondary_id>
    <secondary_id>FIS EC07-90276</secondary_id>
    <nct_id>NCT00860366</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Combined Treatment With Uric Acid and rtPA in Acute Ischemic Stroke</brief_title>
  <acronym>Urico-Ictus</acronym>
  <official_title>Randomized, Double Blind Study Assessing the Clinical Efficacy of Combined Treatment With Uric Acid and rtPA Administered Intravenously in Acute Ischemic Stroke Patients Within the First 4.5 Hours of Symptoms Onset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angel Chamorro, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Carlos III Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the combined treatment with Uric Acid and
      rtPA is superior to rtPA alone in terms of clinical efficacy in acute ischemic stroke
      patients treated within the first 4.5 hours of symptoms onset.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxidative stress is a major contributor to brain damage in patients with ischemic stroke.
      Uric acid (UA) is an endogenous product derived from the metabolism of purins which in man is
      responsable of the 60% of the total antioxidant capacity of the organism. Recent experimental
      evidences gathered by our and other research groups have shown that the exogenous
      administration of UA is neuroprotective both in cortical and subcortical brain areas as the
      result of its antioxidant properties. In these studies, animals treated with UA disclosed
      smaller brain infarction after transient focal ischemia, both using the intraluminal model or
      after the injection of autologous clots. Moreover, our group first described greater
      neuroprotection in animals pretreated with rtPA (alteplase). Likewise, we have recently shown
      that the administration of UA was free of serious adverse effects in stroke patients
      receiving rtPA within 3 hours of stroke onset. Yet, preliminary data suggested that this
      intervention might translate into clinical benefits at 3 months follow-up. Based on these
      data, we aim to conduct a phase 3, randomized, double-blind, controlled trial assessing the
      clinical efficacy of UA administration in acute ischemic stroke patients. Currently, rtPA is
      the only approved therapy for stroke patients within the first hours of clinical onset, and
      oxidative stress is thought particularly relevant following ischemia/reperfusion. Based on
      this ground, we aim to conduct this phase 3 clinical trial in ischemic stroke patients which
      are currently treated with rtPA within the 4'5 hour window.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients achieving a mRS of 0 to 1 at 3 months after treatment, or 2 in those patients with a mRS 2 prior to the inclusion in the study</measure>
    <time_frame>90 days after the inclusion.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with NIHSS &lt;2 at 2 hours after completing the experimental treatment.</measure>
    <time_frame>2 hours after completing the experimental treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with NIHSS &lt;1 at day 90.</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving a Barthel scale of 95 to 100 at day 90</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality within the first 90 days.</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Infarction Volume measured by means of MRI or multimodal CT at 72 hours of onset (in specific centers)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with an intracranial hemorrhage associated to a worsening of 4 points in the NIHSS within the first 36 hours of treatment.</measure>
    <time_frame>36 hours.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">421</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Uric Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion of 1 gram of Uric Acid dissolved in vehicle (500 ml of 0'1% Lithium Carbonate and 5% Mannitol).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Uric Acid</intervention_name>
    <description>1 gram dissolved in a vehicle containing 500 ml of 0'1% Lithium Carbonate and 5% Mannitol, IV (in the vein), single dose.</description>
    <arm_group_label>Uric Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age older than 18 years old.

          -  Acute ischemic stroke treated with rtPA within the first 4.5 hours of clinical onset.
             Baseline National Institute of Health Stroke Scale (NIHSS) &gt;6 and &lt;25, and modified
             Rankin Scale (mRS) of 2 prior to the stroke.

          -  Cranial CT disclosing the absence of blood in the CNS.

          -  Informed consent.

        Exclusion criteria:

          -  Presence of any of the valid exclusion criteria for the administration of rtPA in the
             current clinical practise.

          -  History of gout with or without history of gouty nephropathy, or uric lithiasis.
             Asymptomatic hiperuricemia under chronic treatment with allopurinol, or chronic
             treatment with lithium.

          -  Chronic renal insufficiency (baseline creatinine &gt; 1,5mg/dl).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angel Chamorro, MD, PhD.</last_name>
    <role>Study Director</role>
    <affiliation>Comprehensive Stroke Center, Hospital Clínic Barcelona, Spain.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Bellvitge</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitària del Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Mútua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu y Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Chamorro A, Obach V, Cervera A, Revilla M, Deulofeu R, Aponte JH. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke. 2002 Apr;33(4):1048-52.</citation>
    <PMID>11935059</PMID>
  </reference>
  <reference>
    <citation>Chamorro A, Planas AM. Yin and yang of uric acid in patients with stroke. Stroke. 2004 Jan;35(1):e11-2; author reply e11-2. Epub 2003 Dec 11.</citation>
    <PMID>14671231</PMID>
  </reference>
  <reference>
    <citation>Chamorro A, Planas AM, Muner DS, Deulofeu R. Uric acid administration for neuroprotection in patients with acute brain ischemia. Med Hypotheses. 2004;62(2):173-6.</citation>
    <PMID>14962621</PMID>
  </reference>
  <reference>
    <citation>Romanos E, Planas AM, Amaro S, Chamorro A. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab. 2007 Jan;27(1):14-20. Epub 2006 Apr 5.</citation>
    <PMID>16596120</PMID>
  </reference>
  <reference>
    <citation>Amaro S, Soy D, Obach V, Cervera A, Planas AM, Chamorro A. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke. Stroke. 2007 Jul;38(7):2173-5. Epub 2007 May 24.</citation>
    <PMID>17525395</PMID>
  </reference>
  <reference>
    <citation>Amaro S, Planas AM, Chamorro A. Uric acid administration in patients with acute stroke: a novel approach to neuroprotection. Expert Rev Neurother. 2008 Feb;8(2):259-70. doi: 10.1586/14737175.8.2.259. Review.</citation>
    <PMID>18271711</PMID>
  </reference>
  <reference>
    <citation>Amaro S, Chamorro Á. Translational stroke research of the combination of thrombolysis and antioxidant therapy. Stroke. 2011 May;42(5):1495-9. doi: 10.1161/STROKEAHA.111.615039. Epub 2011 Apr 7.</citation>
    <PMID>21474803</PMID>
  </reference>
  <reference>
    <citation>Amaro S, Urra X, Gómez-Choco M, Obach V, Cervera A, Vargas M, Torres F, Rios J, Planas AM, Chamorro A. Uric acid levels are relevant in patients with stroke treated with thrombolysis. Stroke. 2011 Jan;42(1 Suppl):S28-32. doi: 10.1161/STROKEAHA.110.596528. Epub 2010 Dec 16.</citation>
    <PMID>21164140</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2009</study_first_submitted>
  <study_first_submitted_qc>March 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2009</study_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Angel Chamorro, MD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Acute ischemic stroke</keyword>
  <keyword>thrombolysis</keyword>
  <keyword>alteplase</keyword>
  <keyword>uric acid</keyword>
  <keyword>neuroprotection</keyword>
  <keyword>oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Mannitol</mesh_term>
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

